Int J Biol Sci 2023; 19(2):552-570. doi:10.7150/ijbs.76187 This issue Cite


Targeting Breast Cancer Stem Cells

Lu Zhang1#, Wenmin Chen2,3#, Suling Liu1,4✉, Ceshi Chen2,5,6✉

1. Fudan University Shanghai Cancer Center & Institutes of Biomedical Sciences; State Key Laboratory of Genetic Engineering; Cancer Institutes; Key Laboratory of Breast Cancer in Shanghai; The Shanghai paracrine Key Laboratory of Medical Epigenetics; Shanghai Key Laboratory of Radiation Oncology; The International Co-laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology; Shanghai Medical College; Fudan University, Shanghai 200032, China.
2. Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Kunming 650201, China.
3. Kunming College of Life Sciences, the University of the Chinese Academy of Sciences, Kunming 650201, China.
4. Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, Nanjing Medical University, Nanjing 211166, China.
5. Academy of Biomedical Engineering, Kunming Medical University, Kunming 650500, China.
6. The Third Affiliated Hospital, Kunming Medical University, Kunming 650118, China.
#Equal contributions to this work.

Zhang L, Chen W, Liu S, Chen C. Targeting Breast Cancer Stem Cells. Int J Biol Sci 2023; 19(2):552-570. doi:10.7150/ijbs.76187.
Other styles

File import instruction


Graphic abstract

The potential roles of breast cancer stem cells (BCSCs) in tumor initiation and recurrence have been recognized for many decades. Due to their strong capacity for self-renewal and differentiation, BCSCs are the major reasons for poor clinical outcomes and low therapeutic response. Several hypotheses on the origin of cancer stem cells have been proposed, including critical gene mutations in stem cells, dedifferentiation of somatic cells, and cell plasticity remodeling by epithelial-mesenchymal transition (EMT) and the tumor microenvironment. Moreover, the tumor microenvironment, including cellular components and cytokines, modulates the self-renewal and therapeutic resistance of BCSCs. Small molecules, antibodies, and chimeric antigen receptor (CAR)-T cells targeting BCSCs have been developed, and their applications in combination with conventional therapies are undergoing clinical trials. In this review, we focus on the features of BCSCs, emphasize the major factors and tumor environment that regulate the stemness of BCSCs, and discuss potential BCSC-targeting therapies.

Keywords: Breast cancer stem cell, Epithelial-Mesenchymal Transition, Tumor microenvironment, Therapeutic strategies

Citation styles

Zhang, L., Chen, W., Liu, S., Chen, C. (2023). Targeting Breast Cancer Stem Cells. International Journal of Biological Sciences, 19(2), 552-570.

Zhang, L.; Chen, W.; Liu, S.; Chen, C. Targeting Breast Cancer Stem Cells. Int. J. Biol. Sci. 2023, 19 (2), 552-570. DOI: 10.7150/ijbs.76187.

Zhang L, Chen W, Liu S, Chen C. Targeting Breast Cancer Stem Cells. Int J Biol Sci 2023; 19(2):552-570. doi:10.7150/ijbs.76187.

Zhang L, Chen W, Liu S, Chen C. 2023. Targeting Breast Cancer Stem Cells. Int J Biol Sci. 19(2):552-570.

This is an open access article distributed under the terms of the Creative Commons Attribution License ( See for full terms and conditions.
Popup Image